دورية أكاديمية
أعرض في EDS

New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization.

التفاصيل البيبلوغرافية
العنوان: New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization.
المؤلفون: Mohammed HHH; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag, Egypt., Abd El-Hafeez AA; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.; Cancer Biology Department, Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Cairo, Egypt., Ebeid K; Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt.; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.; Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Manufacturing, Deraya University, New Minia City, Minia, Egypt., Mekkawy AI; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.; Department of Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Sohag University, Sohag, Egypt., Abourehab MAS; Department of Pharmaceutics, Faculty of Pharmacy, Umm Al Qura University, Makkah, Saudi Arabia., Wafa EI; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA., Alhaj-Suliman SO; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA., Salem AK; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA., Ghosh P; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.; Department of Medicine, University of California San Diego, La Jolla, CA, USA.; Rebecca and John Moore Comprehensive Cancer Center, University of California San Diego, La Jolla, CA, USA.; Veterans Affairs Medical Center, La Jolla, CA, USA., Abuo-Rahma GEA; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Deraya University, Minia, Egypt., Hayallah AM; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut, Egypt.; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Sphinx University, New Assiut, Egypt., Abbas SH; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.
المصدر: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 1346-1363.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101150203 Publication Model: Print Cited Medium: Internet ISSN: 1475-6374 (Electronic) Linking ISSN: 14756366 NLM ISO Abbreviation: J Enzyme Inhib Med Chem Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basingstoke, UK : Taylor & Francis, c2002-
مواضيع طبية MeSH: Antineoplastic Agents*/metabolism , Antineoplastic Agents*/pharmacology , Chalcone*/pharmacology , Chalcones*/metabolism , Chalcones*/pharmacology, Caco-2 Cells ; Cell Line, Tumor ; Cell Proliferation ; Ciprofloxacin/pharmacology ; DNA Damage ; DNA Topoisomerases, Type I/metabolism ; DNA Topoisomerases, Type II/metabolism ; Doxorubicin/pharmacology ; Drug Screening Assays, Antitumor ; Humans ; Molecular Structure ; Polymerization ; Structure-Activity Relationship ; Triazoles/pharmacology ; Tubulin/metabolism
مستخلص: A series of novel 1,2,3-triazole-linked ciprofloxacin-chalcones 4a-j were synthesised as potential anticancer agents. Hybrids 4a-j exhibited remarkable anti-proliferative activity against colon cancer cells. Compounds 4a-j displayed IC 50 s ranged from 2.53-8.67 µM, 8.67-62.47 µM, and 4.19-24.37 µM for HCT116, HT29, and Caco-2 cells; respectively, whereas the doxorubicin, showed IC 50 values of 1.22, 0.88, and 4.15 µM. Compounds 4a, 4b, 4e, 4i, and 4j were the most potent against HCT116 with IC 50 values of 3.57, 4.81, 4.32, 4.87, and 2.53 µM, respectively, compared to doxorubicin (IC 50 = 1.22 µM). Also, hybrids 4a, 4b, 4e, 4i, and 4j exhibited remarkable inhibitory activities against topoisomerase I, II, and tubulin polymerisation. They increased the protein expression level of γH2AX, indicating DNA damage, and arrested HCT116 in G2/M phase, possibly through the ATR/CHK1/Cdc25C pathway. Thus, the novel ciprofloxacin hybrids could be exploited as potential leads for further investigation as novel anticancer medicines to fight colorectal carcinoma.
References: Eur J Med Chem. 2014 Oct 6;85:758-77. (PMID: 25137491)
J Med Chem. 2005 Oct 20;48(21):6523-43. (PMID: 16220969)
Drug Discov Today. 2017 Oct;22(10):1572-1581. (PMID: 28676407)
Eur J Med Chem. 2019 May 15;170:173-194. (PMID: 30897396)
Arch Pharm (Weinheim). 2019 Jul;352(7):e1800376. (PMID: 31215674)
Curr Med Chem Anticancer Agents. 2003 Nov;3(6):439-50. (PMID: 14529452)
Science. 2013 Apr 26;340(6131):457-60. (PMID: 23558174)
Eur J Med Chem. 2020 Mar 1;189:112062. (PMID: 31986406)
Eur J Cancer. 1991;27(7):897-900. (PMID: 1834124)
Eur J Med Chem. 2011 Dec;46(12):6025-38. (PMID: 22036229)
Biomed Pharmacother. 2009 Mar;63(3):216-20. (PMID: 18328669)
Drug Discov Today. 2007 Jan;12(1-2):34-42. (PMID: 17198971)
Eur J Med Chem. 2020 Dec 15;208:112756. (PMID: 32942186)
Invest New Drugs. 2019 Aug;37(4):784-790. (PMID: 30740631)
Antimicrob Agents Chemother. 1994 Jan;38(1):130-3. (PMID: 8141566)
Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40. (PMID: 12042765)
Curr Med Chem. 2019;26(17):3132-3149. (PMID: 29446718)
Eur J Med Chem. 2013 Nov;69:427-38. (PMID: 24090914)
Biochem Cell Biol. 2017 Jun;95(3):379-384. (PMID: 28177759)
Eur J Cancer. 1993;29A(3):395-9. (PMID: 8398340)
Curr Clin Pharmacol. 2010 Feb;5(1):1-29. (PMID: 19891604)
Eur J Med Chem. 2018 May 10;151:705-722. (PMID: 29660690)
Bioorg Chem. 2017 Apr;71:30-54. (PMID: 28126288)
BMC Cancer. 2015 Aug 11;15:581. (PMID: 26260159)
Eur J Med Chem. 2017 Jan 5;125:143-189. (PMID: 27662031)
In Vitro Cell Dev Biol Anim. 2015 Jan;51(1):92-101. (PMID: 25148824)
J Enzyme Inhib Med Chem. 2016 Oct;31(5):796-809. (PMID: 26226179)
J Med Chem. 2019 Jan 24;62(2):420-444. (PMID: 30035545)
Eur J Med Chem. 2018 Jul 15;155:772-781. (PMID: 29945100)
Biomed Pharmacother. 2005 Oct;59(9):501-10. (PMID: 16263236)
Biochemistry. 1989 May 2;28(9):3879-85. (PMID: 2546584)
Anticancer Agents Med Chem. 2018;18(1):21-37. (PMID: 27528183)
Chem Biol Drug Des. 2015 Oct;86(4):410-23. (PMID: 25643871)
Bioorg Chem. 2017 Dec;75:86-98. (PMID: 28922629)
Eur J Med Chem. 2018 May 10;151:339-350. (PMID: 29635166)
Annu Rev Biochem. 2001;70:369-413. (PMID: 11395412)
J Toxicol. 2016;2016:7651047. (PMID: 26880913)
Adv Exp Med Biol. 2012;732:1-8. (PMID: 22210248)
J Biol Chem. 1997 Jul 4;272(27):17118-25. (PMID: 9202030)
Molecules. 2015 Jan 14;20(1):1357-76. (PMID: 25594346)
Eur J Med Chem. 2018 Jan 1;143:1277-1300. (PMID: 29126724)
Biomed Pharmacother. 2019 Mar;111:934-946. (PMID: 30841473)
Eur J Med Chem. 2019 Mar 15;166:206-223. (PMID: 30711831)
Eur J Med Chem. 2020 Feb 1;187:111970. (PMID: 31881454)
Bioorg Chem. 2021 Jan;106:104422. (PMID: 33248713)
Eur J Pharm Sci. 2021 Jan 1;156:105594. (PMID: 33059042)
Eur J Med Chem. 2021 Jan 1;209:112904. (PMID: 33077264)
Eur J Med Chem. 2012 Jan;47(1):615-8. (PMID: 22093760)
Curr Opin Microbiol. 1999 Oct;2(5):504-8. (PMID: 10508721)
Bioorg Med Chem. 2009 Aug 1;17(15):5396-407. (PMID: 19595598)
Bioorg Chem. 2020 Jan;95:103565. (PMID: 31927336)
Eur J Med Chem. 2005 Apr;40(4):361-9. (PMID: 15804535)
Bioorg Med Chem. 2018 Aug 7;26(14):3958-3966. (PMID: 29954683)
Arch Pharm (Weinheim). 2022 Jan;355(1):e2100158. (PMID: 34559414)
J Med Chem. 2014 Oct 9;57(19):7874-87. (PMID: 24946140)
J Vis Exp. 2017 Nov 3;(129):. (PMID: 29155797)
Int Immunopharmacol. 2011 Mar;11(3):295-309. (PMID: 21184860)
Eur J Med Chem. 2017 Sep 29;138:501-513. (PMID: 28692915)
Eur J Med Chem. 2019 Apr 15;168:357-372. (PMID: 30826511)
Biochem Pharmacol. 2008 Mar 15;75(6):1272-81. (PMID: 18191106)
Molecules. 2022 Jan 25;27(3):. (PMID: 35164037)
Bioorg Chem. 2019 Mar;84:150-163. (PMID: 30502626)
Int J Pharm. 2021 Sep 5;606:120876. (PMID: 34252520)
Bioorg Med Chem. 2016 Oct 1;24(19):4636-4646. (PMID: 27555286)
Transl Oncol. 2021 Oct;14(10):101174. (PMID: 34243011)
Eur J Med Chem. 2018 Oct 5;158:917-936. (PMID: 30261467)
Evid Based Complement Alternat Med. 2013;2013:815621. (PMID: 23690855)
Bioorg Med Chem Lett. 2013 Dec 1;23(23):6292-5. (PMID: 24138941)
Bioorg Med Chem Lett. 2020 Dec 1;30(23):127610. (PMID: 33045329)
Eur J Med Chem. 2019 Dec 1;183:111700. (PMID: 31546197)
Expert Opin Ther Pat. 2017 Apr;27(4):415-426. (PMID: 27897041)
معلومات مُعتمدة: P30 ES005605 United States ES NIEHS NIH HHS
فهرسة مساهمة: Keywords: Click synthesis; DNA damage; HCT116 cells; chalcone; ciprofloxacin; cytotoxicity; topoisomerase I and II inhibitors; tubulin polymerisation inhibition
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Chalcones)
0 (Triazoles)
0 (Tubulin)
5E8K9I0O4U (Ciprofloxacin)
5S5A2Q39HX (Chalcone)
80168379AG (Doxorubicin)
EC 5.99.1.2 (DNA Topoisomerases, Type I)
EC 5.99.1.3 (DNA Topoisomerases, Type II)
تواريخ الأحداث: Date Created: 20220513 Date Completed: 20220517 Latest Revision: 20220907
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9116245
DOI: 10.1080/14756366.2022.2072308
PMID: 35548854
قاعدة البيانات: MEDLINE
الوصف
تدمد:1475-6374
DOI:10.1080/14756366.2022.2072308